Acthar for Treatment of Post-transplant FSGS

Summary

This is an open label safety and feasibility trial using Acthar® in addition to center-specific standard therapy including plasma exchange, for treatment of post transplant recurrent FSGS and post transplant recurrent idiopathic membranous nephropathy. Subjects will receive Acthar® 40 units subcutaneously (SC) twice weekly for two weeks then 80 units SC twice weekly for 24 weeks.

Timeline

Start

2021-03

Primary completion

2021-07-31

Completion

2021-07-31

Drugs

Indications